Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VRTX

Vertex Pharmaceuticals, Inc.

Dec 04 • 04:00PM ET

350.63

Dollar change -0.53
Percentage change -0.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX, S&P 500	P/E	26.32	EPS (ttm)	13.32	Insider Own	0.28%	Shs Outstand	257.01M	Perf Week	0.13%
Market Cap	90.35B	Forward P/E	21.32	EPS next Y	16.45	Insider Trans	-14.63%	Shs Float	256.94M	Perf Month	-6.88%
Income	3.47B	PEG	2.46	EPS next Q	4.04	Inst Own	93.14%	Short Float / Ratio	0.98% / 2.07	Perf Quarter	0.68%
Sales	9.57B	P/S	9.44	EPS this Y	0.43%	Inst Trans	1.20%	Short Interest	2.51M	Perf Half Y	4.85%
Book/sh	64.05	P/B	5.47	EPS next Y	10.07%	ROA	18.06%	Target Price	399.46	Perf Year	9.31%
Cash/sh	46.32	P/C	7.57	EPS next 5Y	10.70%	ROE	23.49%	52W Range	282.21 - 387.42	Perf YTD	21.42%
Dividend	-	P/FCF	21.49	EPS past 5Y	65.26%	ROI	20.11%	52W High	-9.50%	Beta	0.38
Dividend %	-	Quick Ratio	3.89	Sales past 5Y	29.17%	Gross Margin	87.69%	52W Low	24.24%	ATR	7.72
Employees	4800	Current Ratio	4.08	Sales Q/Q	9.33%	Oper. Margin	39.90%	RSI (14)	43.79	Volatility	1.77% 2.39%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	10.80%	Profit Margin	36.26%	Rel Volume	1.22	Prev Close	351.16
Shortable	Yes	LT Debt/Eq	0.05	Earnings	Nov 06 AMC	Payout	0.00%	Avg Volume	1.21M	Price	350.63
Recom	1.63	SMA20	-2.92%	SMA50	-2.77%	SMA200	3.05%	Volume	1,469,504	Change	-0.15%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-23	Initiated	William Blair	Outperform	$382
May-04-23	Resumed	Piper Sandler	Overweight	$385
Mar-21-23	Initiated	Bernstein	Outperform	$344
Jan-18-23	Initiated	Canaccord Genuity	Hold	$311
Jan-17-23	Upgrade	SVB Leerink	Mkt Perform → Outperform	$374
Dec-19-22	Downgrade	Jefferies	Buy → Hold	$340
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$365
Jun-01-22	Upgrade	Maxim Group	Hold → Buy	$325
May-23-22	Initiated	SVB Leerink	Mkt Perform	$265
May-06-22	Downgrade	Robert W. Baird	Outperform → Neutral	$250
May-03-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$250
Feb-03-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$269
Jan-27-22	Reiterated	Wolfe Research	Outperform	$271 → $282
Jan-27-22	Reiterated	Stifel	Hold	$213 → $222
Jan-27-22	Reiterated	RBC Capital Mkts	Outperform	$268 → $269
Jan-27-22	Reiterated	Morgan Stanley	Underweight	$203 → $208
Jan-27-22	Reiterated	JP Morgan	Overweight	$260 → $288
Jan-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$202 → $274
Dec-09-21	Initiated	Wells Fargo	Overweight	$270
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$202

Show Previous Ratings

Today 08:30AM	You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. (Motley Fool)
05:51AM	A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own. (Motley Fool)
05:30AM	Where Will Vertex Pharmaceuticals Be in 10 Years? (Motley Fool)
Dec-03-23 06:54AM	3 No-Brainer Growth Stocks to Buy in December (Motley Fool)
05:53AM	Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now (Motley Fool)
05:00AM	Loading…
Dec-02-23 05:00AM	5 Top Stocks to Buy Before 2024 (Motley Fool)
Dec-01-23 06:15AM	Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool)
Nov-29-23 01:59PM	Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older (PR Newswire)
Nov-27-23 05:30AM	5 Stocks You Can Confidently Invest $500 In Right Now (Motley Fool)
Nov-25-23 07:00AM	2 Healthcare Stocks That Could Help Set You Up for Life (Motley Fool)
05:06AM	4 First-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Nov-24-23 11:48AM	Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids (Zacks)
09:21AM	Morning Brew: iRobot Surges on Amazon Deal Approval, Tesla Eyes India Factory (GuruFocus.com)
09:13AM	Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations (Business Wire)
07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
09:05AM	Loading…
Nov-23-23 09:05AM	European Commission Approves KAFTRIO in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 (Business Wire)
05:50AM	Prediction: 3 Stocks That Could Trounce the Market (Motley Fool)
Nov-22-23 07:30AM	Is CRISPR Therapeutics the Best Gene-Editing Stock? (Motley Fool)
03:04AM	Insider Sell Analysis: EVP & CFO Charles F. Wagner Jr. ... (GuruFocus.com)
Nov-21-23 06:00AM	Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year (Zacks)
Nov-19-23 05:30AM	Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire? (Motley Fool)
Nov-18-23 06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 01:26PM	Vertex Shares Dip on Anxiety Over Pain Pill Trial (Barrons.com)
11:12AM	Why CRISPR Therapeutics Stock Is Jumping Again Today (Motley Fool)
09:03AM	Insider Sell Alert: EVP and CMO Carmen Bozic Sells 5,650 Shares of Vertex Pharmaceuticals Inc (VRTX) (GuruFocus.com)
Nov-16-23 07:05PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
04:06PM	Market Today: CRISPR Therapeutics and Vertex Pharmaceuticals Make History with UK Drug Approval (GuruFocus.com)
04:03PM	Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug (Investor's Business Daily)
01:26PM	U.K. Approves First Genetic Scissors Treatment (Barrons.com)
07:45AM	Is Vertex Pharmaceuticals Stock a Buy Now? (Motley Fool)
07:15AM	Loading…
07:15AM	Worlds first CRISPR medicine approved in UK for sickle cell, beta thalassemia (BioPharma Dive)
04:57AM	UK approves Crispr gene editing therapy in global first (Financial Times)
01:45AM	Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia (Business Wire)
Nov-15-23 04:05PM	Market Today: Coatue Management Adjusts Holdings, Vertex Pharmaceuticals Drops, Alibaba Earnings (GuruFocus.com) -5.57%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool)
Nov-13-23 06:07PM	12 Best Low Beta Stocks To Buy (Insider Monkey)
Nov-12-23 05:50AM	3 Revolutionary Stocks I'd Buy Right Now Without Hesitation (Motley Fool)
Nov-11-23 08:30AM	1 No-Brainer Stock to Buy and Hold for 10 Years (Motley Fool)
06:50AM	3 Growth Stocks to Buy Right Now Without Any Hesitation (Motley Fool)
05:06AM	4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Nov-09-23 05:30AM	This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues (Motley Fool)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 10:07AM	Why CRISPR Therapeutics Stock Could Be About to Take Off (Motley Fool)
09:30AM	Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:50AM	4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked (Motley Fool)
12:08AM	The Vertex Pharmaceuticals Inc (VRTX) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-07-23 04:23PM	Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus (Investor's Business Daily)
04:21PM	These Stocks Moved the Most Today: Datadog, Uber, D.R. Horton, Sanmina, Alteryx, Planet Fitness, DigitalOcean, and More (Barrons.com)
01:29PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
01:23PM	These Stocks Are Moving the Most Today: Datadog, Uber, D.R. Horton, Sanmina, Alteryx, Planet Fitness, DigitalOcean, and More (Barrons.com)
11:13AM	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:50AM	Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View (Zacks)
07:16AM	Q3 2023 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:15AM	Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-06-23 06:02PM	Vertex Pharma misses sales estimates on weak demand for older CF treatments (Reuters)
05:27PM	Vertex, An IBD Tech Leader, Slouches After Its Bread-And-Butter Drug Misses Some Estimates (Investor's Business Daily)
05:25PM	Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates (Zacks)
04:54PM	Vertex Pharmaceuticals Inc (VRTX) Reports 6% Increase in Q3 2023 Product Revenue (GuruFocus.com)
04:25PM	Vertex: Q3 Earnings Snapshot (Associated Press Finance)
04:21PM	IBD Tech Leader Vertex Boosts Outlook After Strong Earnings (Investor's Business Daily)
04:01PM	Vertex Reports Third Quarter 2023 Financial Results (Business Wire)
11:08AM	England's young cystic fibrosis patients face new treatment worry (Reuters)
Nov-03-23 09:56AM	Why CRISPR Therapeutics Stock Charged Northward This Week (Motley Fool)
08:05AM	Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA (Motley Fool)
07:03AM	EVP and CMO Carmen Bozic Sells 5,651 Shares of Vertex Pharmaceuticals Inc (GuruFocus.com)
Nov-02-23 05:45PM	Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts (Zacks)
11:23AM	This New Pain Pill Could Replace Opioids. Its an Opportunity for Investors. (Barrons.com)
09:02AM	Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
08:30AM	Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA at the North American Cystic Fibrosis Conference (Business Wire)
05:30AM	One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? (Motley Fool)
Nov-01-23 04:16PM	Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug (Investor's Business Daily)
Oct-31-23 06:26PM	FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study (Reuters)
03:43PM	FDA Advisors Review Crispr Gene-Editing Treatment for Sickle Cell Anemia (Barrons.com)
06:50AM	FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia (Barrons.com)
05:00AM	A play-by-play of the FDAs meeting on Vertex, CRISPRs sickle cell therapy (BioPharma Dive)
Oct-30-23 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:18AM	5 Reasons Beam Therapeutics Remains a Risky Stock (Motley Fool)
09:00AM	Vertex (VRTX) to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-28-23 05:50AM	Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade (Motley Fool)
Oct-27-23 06:15PM	Market Today: Mixed Market Performance Amidst Key Stock Developments (GuruFocus.com)
05:45PM	Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors (Zacks)
12:44PM	FDA Staff Raises Concerns Over Lack of Safety Data for Sickle-Cell Treatment (Bloomberg)
10:15AM	Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money (Motley Fool)
09:27AM	UPDATE 3-US FDA advisers to determine need for more studies of Vertex/CRISPR gene therapy (Reuters)
09:10AM	US FDA staff says safety risks not clear for Vertex/CRISPR's gene therapy (Reuters)
05:20AM	2 Healthcare Stocks That Could Make You Richer (Motley Fool)
Oct-26-23 10:00AM	This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024 (Motley Fool)
10:00AM	2 Top Healthcare Stocks Defying the Bear Market (Motley Fool)
09:15AM	2 Best Healthcare Stocks to Buy Right Now (Motley Fool)
08:22AM	CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards? (Zacks)
08:00AM	Vertex to Present at Upcoming Investor Conferences (Business Wire)
06:15AM	Vertex Pharmaceuticals: Buy at the High? (Motley Fool)
05:20AM	3 Healthcare Stocks to Buy and Hold for the Next 10 Years (Motley Fool)
05:05AM	2 No-Brainer Growth Stocks to Buy Right Now (Motley Fool)
Oct-25-23 09:45AM	3 Red-Hot Growth Stocks That Are Still Cheap Buys (Motley Fool)
08:45AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Oct-24-23 05:30AM	The Best Stocks to Invest $5,000 In Right Now (Motley Fool)
Oct-23-23 05:50PM	Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)
Oct-22-23 06:55AM	3 Unstoppable Stocks to Buy Sooner Rather Than Later (Motley Fool)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 20	Sale	349.88	3,000	1,049,640	46,693	Nov 21 04:07 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Nov 15	Sale	369.92	35	12,947	58,814	Nov 17 04:16 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 15	Sale	369.92	19	7,028	32,038	Nov 17 04:11 PM
Bozic Carmen	EVP and CMO	Nov 14	Sale	380.82	5,650	2,151,633	29,302	Nov 16 04:15 PM
Kewalramani Reshma	CEO & President	Nov 13	Sale	377.00	5,097	1,921,569	113,809	Nov 15 04:16 PM
SACHS BRUCE I	Director	Nov 06	Option Exercise	127.54	11,250	1,434,825	51,250	Nov 08 04:11 PM
SACHS BRUCE I	Director	Nov 06	Sale	385.00	11,250	4,331,250	40,000	Nov 08 04:11 PM
Bozic Carmen	EVP and CMO	Oct 31	Sale	355.92	5,651	2,011,304	34,952	Nov 02 04:07 PM
Bozic Carmen	EVP and CMO	Oct 17	Sale	373.25	5,651	2,109,236	40,603	Oct 19 04:18 PM
Bhatia Sangeeta N.	Director	Oct 17	Sale	375.00	243	91,125	3,901	Oct 19 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Oct 16	Sale	374.00	12,962	4,847,788	22,425	Oct 18 04:17 PM
Bhatia Sangeeta N.	Director	Oct 06	Sale	360.00	242	87,120	4,144	Oct 11 04:14 PM
Bozic Carmen	EVP and CMO	Oct 03	Sale	345.28	5,651	1,951,177	46,254	Oct 05 04:30 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02	Sale	346.76	610	211,524	10,569	Oct 03 04:07 PM
Bozic Carmen	EVP and CMO	Sep 19	Sale	351.00	5,651	1,983,501	51,905	Sep 21 04:15 PM
Bozic Carmen	EVP and CMO	Sep 05	Sale	352.66	5,651	1,992,882	57,556	Sep 07 04:29 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Aug 23	Sale	355.00	2,500	887,500	48,637	Aug 25 04:14 PM
Kearney Terrence C	Director	Aug 10	Option Exercise	127.54	10,000	1,275,400	16,536	Aug 14 04:09 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 10	Sale	350.00	10,031	3,510,850	58,814	Aug 14 04:05 PM
Kearney Terrence C	Director	Aug 10	Sale	350.00	10,000	3,500,000	6,536	Aug 14 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Aug 10	Sale	345.79	5,750	1,988,293	51,137	Aug 14 04:08 PM
Bhatia Sangeeta N.	Director	Aug 09	Sale	345.51	242	83,613	4,386	Aug 11 04:05 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 09	Sale	345.51	63	21,767	32,038	Aug 11 04:05 PM
SACHS BRUCE I	Director	Jul 17	Option Exercise	127.54	11,250	1,434,825	51,250	Jul 18 04:17 PM
SACHS BRUCE I	Director	Jul 17	Sale	356.75	11,250	4,013,459	40,000	Jul 18 04:17 PM
Kewalramani Reshma	CEO & President	Jul 17	Sale	355.00	7,828	2,778,940	118,906	Jul 18 04:13 PM
Arbuckle Stuart A	EVP, COO	Jun 15	Option Exercise	187.53	8,603	1,613,321	65,159	Jun 20 04:07 PM
Arbuckle Stuart A	EVP, COO	Jun 15	Sale	349.00	8,603	3,002,447	56,556	Jun 20 04:07 PM
Ambrose Kristen	SVP & Chief Accounting Officer	May 30	Sale	329.82	289	95,318	6,838	Jun 01 04:12 PM
Arbuckle Stuart A	EVP, COO	May 30	Sale	329.82	82	27,045	56,556	Jun 01 04:16 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 08	Sale	350.00	2,850	997,500	32,038	May 09 04:15 PM
LEIDEN JEFFREY M	Executive Chairman	May 08	Sale	349.00	1,125	392,625	35,387	May 09 04:10 PM
LEIDEN JEFFREY M	Executive Chairman	May 05	Sale	349.56	879	307,262	36,512	May 09 04:10 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 05	Sale	350.03	422	147,713	34,888	May 09 04:15 PM
LEIDEN JEFFREY M	Executive Chairman	May 03	Sale	350.11	4,508	1,578,301	37,391	May 04 04:50 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 03	Sale	350.74	2,781	975,418	35,310	May 04 04:51 PM
LEIDEN JEFFREY M	Executive Chairman	May 02	Sale	349.89	6,450	2,256,761	41,899	May 04 04:50 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 02	Sale	350.66	1,622	568,768	38,091	May 04 04:51 PM
Bhatia Sangeeta N.	Director	May 02	Sale	348.28	580	202,004	4,628	May 03 04:44 PM
Kewalramani Reshma	CEO & President	Apr 27	Sale	339.08	3,317	1,124,726	126,652	May 01 04:26 PM
SACHS BRUCE I	Director	Apr 12	Option Exercise	72.14	21,300	1,536,582	62,510	Apr 14 04:14 PM
SACHS BRUCE I	Director	Apr 12	Sale	326.73	21,300	6,959,422	41,210	Apr 14 04:14 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 12	Sale	326.70	7,567	2,472,164	39,713	Apr 14 04:19 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 04	Sale	315.81	522	164,854	47,280	Apr 06 04:23 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 24	Sale	305.38	1,768	539,912	49,611	Mar 28 04:13 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 17	Sale	296.39	2,000	592,786	51,379	Mar 21 04:21 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Mar 16	Sale	300.59	2,746	825,423	49,268	Mar 20 04:26 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 13	Sale	293.83	2,666	783,346	53,379	Mar 14 04:22 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 10	Sale	289.61	2,088	604,709	56,045	Mar 14 04:22 PM
Arbuckle Stuart A	EVP, COO	Feb 27	Sale	287.47	5,034	1,447,143	56,556	Feb 28 04:47 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 27	Sale	287.51	4,238	1,218,449	32,038	Feb 28 04:40 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 27	Sale	287.55	1,207	347,072	7,303	Feb 28 04:44 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 27	Sale	287.48	354	101,768	56,805	Feb 28 05:11 PM
Arbuckle Stuart A	EVP, COO	Feb 22	Sale	294.33	2,401	706,679	66,304	Feb 24 04:06 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 21	Sale	293.77	4,002	1,175,676	40,246	Feb 22 04:25 PM
Arbuckle Stuart A	EVP, COO	Feb 21	Sale	293.75	2,402	705,596	68,705	Feb 22 04:30 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 21	Sale	293.75	480	141,002	60,467	Feb 22 04:48 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 14	Sale	298.70	6,398	1,911,108	47,998	Feb 16 04:11 PM
Arbuckle Stuart A	EVP, COO	Feb 14	Sale	298.68	6,398	1,910,962	75,605	Feb 16 04:14 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 14	Sale	300.39	2,181	655,161	59,734	Feb 16 04:16 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 14	Sale	298.52	320	95,527	65,445	Feb 16 04:18 PM
Arbuckle Stuart A	EVP, COO	Feb 13	Sale	298.92	4,887	1,460,816	82,003	Feb 14 04:53 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 13	Sale	298.90	4,798	1,434,126	54,396	Feb 14 04:49 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 13	Sale	298.99	275	82,223	65,765	Feb 14 05:12 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 13	Sale	300.39	113	33,944	61,915	Feb 14 05:08 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 06	Option Exercise	187.53	1,304	244,539	69,949	Feb 08 04:53 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 06	Sale	306.00	1,304	399,022	68,645	Feb 08 04:53 PM
SACHS BRUCE I	Director	Jan 31	Option Exercise	72.14	1,200	86,568	42,410	Feb 02 04:14 PM
SACHS BRUCE I	Director	Jan 31	Sale	325.01	1,200	390,012	41,210	Feb 02 04:14 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Jan 31	Sale	325.00	106	34,450	37,998	Feb 02 04:18 PM
CARNEY LLOYD	Director	Jan 30	Sale	320.52	2,700	865,406	4,150	Jan 31 04:45 PM
Lee Yuchun	Director	Jan 27	Option Exercise	72.14	1,429	103,088	3,304	Jan 31 04:42 PM
Lee Yuchun	Director	Jan 27	Sale	322.03	1,429	460,177	1,875	Jan 31 04:42 PM
Lee Yuchun	Director	Jan 26	Option Exercise	72.14	4,000	288,560	5,875	Jan 27 04:18 PM
Lee Yuchun	Director	Jan 26	Sale	318.33	4,000	1,273,322	1,875	Jan 27 04:18 PM
Lee Yuchun	Director	Jan 25	Option Exercise	72.14	4,000	288,560	5,875	Jan 27 04:18 PM
Kewalramani Reshma	CEO & President	Jan 25	Sale	315.05	10,000	3,150,500	89,598	Jan 27 04:13 PM
Lee Yuchun	Director	Jan 25	Sale	313.96	4,000	1,255,852	1,875	Jan 27 04:18 PM
Lee Yuchun	Director	Jan 24	Option Exercise	72.14	4,000	288,560	5,875	Jan 25 04:08 PM
Lee Yuchun	Director	Jan 24	Sale	312.69	4,000	1,250,753	1,875	Jan 25 04:08 PM
Lee Yuchun	Director	Jan 23	Option Exercise	72.14	2,129	153,586	4,004	Jan 25 04:08 PM
Lee Yuchun	Director	Jan 23	Sale	312.02	2,129	664,291	1,875	Jan 25 04:08 PM
Lee Yuchun	Director	Jan 18	Option Exercise	72.14	442	31,886	2,317	Jan 19 04:07 PM
Lee Yuchun	Director	Jan 18	Sale	312.17	442	137,979	1,875	Jan 19 04:07 PM
Lee Yuchun	Director	Jan 17	Option Exercise	72.14	4,000	288,560	5,875	Jan 19 04:07 PM
Lee Yuchun	Director	Jan 17	Sale	312.03	4,000	1,248,120	1,875	Jan 19 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRTX

Vertex Pharmaceuticals, Inc.

Upgrade your FINVIZ experience